**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 34‐year‐old woman showed an elevation in ALP during treatment with tenofovir-disoproxil-fumarate for HIV infection.

The woman was diagnosed with SARS‐CoV‐2 infection and was hospitalised. She had been HIV positive, and had been receiving tenofovir-disoproxil-fumarate \[*route and dosage not stated*\], lamivudine and efavirenz for 5 years. At the current admission, her examination was normal except for tachypnoea of an unknown aetiology. On day 3, she complained of chest pain, anorexia, headache and muscle aches. On the same day, she started receiving off-label treatment with oral azithromycin 500 mg/day for 5 days, and hydroxychloroquine 400mg twice on day 3 and 200mg twice daily for the subsequent 5 days. Additionally, she received paracetamol. On day 6, she developed watery non‐bloody diarrhoea. She received ciprofloxacin and oral rehydration salts under suspicion of superimposed GI bacterial infection. Laboratory investigations on day 10 showed marked elevation in ALP \[*time to reaction onset not stated*\], due to tenofovir-disoproxil-fumarate. Her consecutive tests for SARS‐CoV‐2 on day 18 and day 21 were negative, and she was discharged on day 24 \[*reaction outcome not stated*\].
